GlassScriptPrepare for your visit
Latonda E Paymon
Family · Montgomery, AL · NPI 1306080908
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$904.84
in general payments reported to CMS, 2019-2025 · $294 in 2025
The $294 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Who reported paying
General payments only, top 6 by amount.
- Glaxosmithkline, LLC. $347.31
- Amgen INC. $195.26
- Supernus Pharmaceuticals, INC. $165.22
- Takeda Pharmaceuticals U.S.A., INC. $53.05
- Sanofi Pasteur INC. $34.22
- Seqirus USA INC $33.25
Drugs and devices associated with these payments
Repatha Penmenvy Bexsero Qelbree Otezla Beyfortus Flucelvax Flumist Quadrivalent Eucrisa Comirnaty Cibinqo Paxlovid
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Latonda Paymon listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/10430457/latonda-e-paymon